Viral Vector and Plasmid DNA Industry Research Report 2023

Viral Vector and Plasmid DNA Industry Research Report 2023


Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.

Highlights

The global Viral Vector and Plasmid DNA market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
Global Viral Vector and Plasmid DNA key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Europe, and Asia-Pacific, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Viral Vector and Plasmid DNA, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector and Plasmid DNA.
The Viral Vector and Plasmid DNA market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Viral Vector and Plasmid DNA market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vector and Plasmid DNA companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights


In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Brammer Bio
Oxford BioMedica
Cobra Biologics
FinVector
Lonza
BioReliance
MolMed
FUJIFILM Diosynth Biotechnologies
UniQure
Aldevron
Richter-Helm
Eurogentec
OBiO Technology
Yposkesi
Cell and Gene Therapy Catapult
MassBiologics
Biovian
VGXI
Gene Synthesis
PlasmidFactory
Jikai Gene

Product Type Insights

Global markets are presented by Viral Vector and Plasmid DNA type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Viral Vector and Plasmid DNA are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Viral Vector and Plasmid DNA segment by Type

Plasmid DNA
Viral Vector

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Viral Vector and Plasmid DNA market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Viral Vector and Plasmid DNA market.
Viral Vector and Plasmid DNA Segment by Application

Cancer
Virus Infection
Hereditary Disease

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Viral Vector and Plasmid DNA market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vector and Plasmid DNA market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Viral Vector and Plasmid DNA and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Viral Vector and Plasmid DNA industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vector and Plasmid DNA.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Viral Vector and Plasmid DNA companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Frequently Asked Questions

What factors will challenge the Product Name market growth?
Which end-use segment will expand at the fastest CAGR in the Product Name market?
Which are the emerging players in the Product Name market?
How concentrated is the Product Name market?
Which factors are positively contributing to the Product Name market growth?
Which are the novel product innovations in the Product Name market?
Which product segment will emerge as the most lucrative in the Product Name market?
Which factors are increasing the competition in the Product Name market?
Which are the strategic measures taken by the Product Name industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Product Name market in the coming years?


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Viral Vector and Plasmid DNA by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Plasmid DNA
1.2.3 Viral Vector
2.3 Viral Vector and Plasmid DNA by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Cancer
2.3.3 Virus Infection
2.3.4 Hereditary Disease
2.4 Assumptions and Limitations
3 Viral Vector and Plasmid DNA Breakdown Data by Type
3.1 Global Viral Vector and Plasmid DNA Historic Market Size by Type (2018-2023)
3.2 Global Viral Vector and Plasmid DNA Forecasted Market Size by Type (2023-2028)
4 Viral Vector and Plasmid DNA Breakdown Data by Application
4.1 Global Viral Vector and Plasmid DNA Historic Market Size by Application (2018-2023)
4.2 Global Viral Vector and Plasmid DNA Forecasted Market Size by Application (2018-2023)
5 Global Growth Trends
5.1 Global Viral Vector and Plasmid DNA Market Perspective (2018-2029)
5.2 Global Viral Vector and Plasmid DNA Growth Trends by Region
5.2.1 Global Viral Vector and Plasmid DNA Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Viral Vector and Plasmid DNA Historic Market Size by Region (2018-2023)
5.2.3 Viral Vector and Plasmid DNA Forecasted Market Size by Region (2024-2029)
5.3 Viral Vector and Plasmid DNA Market Dynamics
5.3.1 Viral Vector and Plasmid DNA Industry Trends
5.3.2 Viral Vector and Plasmid DNA Market Drivers
5.3.3 Viral Vector and Plasmid DNA Market Challenges
5.3.4 Viral Vector and Plasmid DNA Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Viral Vector and Plasmid DNA Players by Revenue
6.1.1 Global Top Viral Vector and Plasmid DNA Players by Revenue (2018-2023)
6.1.2 Global Viral Vector and Plasmid DNA Revenue Market Share by Players (2018-2023)
6.2 Global Viral Vector and Plasmid DNA Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Viral Vector and Plasmid DNA Head office and Area Served
6.4 Global Viral Vector and Plasmid DNA Players, Product Type & Application
6.5 Global Viral Vector and Plasmid DNA Players, Date of Enter into This Industry
6.6 Global Viral Vector and Plasmid DNA Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Viral Vector and Plasmid DNA Market Size (2018-2029)
7.2 North America Viral Vector and Plasmid DNA Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Viral Vector and Plasmid DNA Market Size by Country (2018-2023)
7.4 North America Viral Vector and Plasmid DNA Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 Europe
8.1 Europe Viral Vector and Plasmid DNA Market Size (2018-2029)
8.2 Europe Viral Vector and Plasmid DNA Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Viral Vector and Plasmid DNA Market Size by Country (2018-2023)
8.4 Europe Viral Vector and Plasmid DNA Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Viral Vector and Plasmid DNA Market Size (2018-2029)
9.2 Asia-Pacific Viral Vector and Plasmid DNA Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Viral Vector and Plasmid DNA Market Size by Country (2018-2023)
9.4 Asia-Pacific Viral Vector and Plasmid DNA Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 Latin America
10.1 Latin America Viral Vector and Plasmid DNA Market Size (2018-2029)
10.2 Latin America Viral Vector and Plasmid DNA Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Viral Vector and Plasmid DNA Market Size by Country (2018-2023)
10.4 Latin America Viral Vector and Plasmid DNA Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Viral Vector and Plasmid DNA Market Size (2018-2029)
11.2 Middle East & Africa Viral Vector and Plasmid DNA Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country (2018-2023)
11.4 Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 Players Profiled
11.1 Brammer Bio
11.1.1 Brammer Bio Company Detail
11.1.2 Brammer Bio Business Overview
11.1.3 Brammer Bio Viral Vector and Plasmid DNA Introduction
11.1.4 Brammer Bio Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.1.5 Brammer Bio Recent Development
11.2 Oxford BioMedica
11.2.1 Oxford BioMedica Company Detail
11.2.2 Oxford BioMedica Business Overview
11.2.3 Oxford BioMedica Viral Vector and Plasmid DNA Introduction
11.2.4 Oxford BioMedica Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.2.5 Oxford BioMedica Recent Development
11.3 Cobra Biologics
11.3.1 Cobra Biologics Company Detail
11.3.2 Cobra Biologics Business Overview
11.3.3 Cobra Biologics Viral Vector and Plasmid DNA Introduction
11.3.4 Cobra Biologics Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.3.5 Cobra Biologics Recent Development
11.4 FinVector
11.4.1 FinVector Company Detail
11.4.2 FinVector Business Overview
11.4.3 FinVector Viral Vector and Plasmid DNA Introduction
11.4.4 FinVector Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.4.5 FinVector Recent Development
11.5 Lonza
11.5.1 Lonza Company Detail
11.5.2 Lonza Business Overview
11.5.3 Lonza Viral Vector and Plasmid DNA Introduction
11.5.4 Lonza Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.5.5 Lonza Recent Development
11.6 BioReliance
11.6.1 BioReliance Company Detail
11.6.2 BioReliance Business Overview
11.6.3 BioReliance Viral Vector and Plasmid DNA Introduction
11.6.4 BioReliance Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.6.5 BioReliance Recent Development
11.7 MolMed
11.7.1 MolMed Company Detail
11.7.2 MolMed Business Overview
11.7.3 MolMed Viral Vector and Plasmid DNA Introduction
11.7.4 MolMed Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.7.5 MolMed Recent Development
11.8 FUJIFILM Diosynth Biotechnologies
11.8.1 FUJIFILM Diosynth Biotechnologies Company Detail
11.8.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.8.3 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Introduction
11.8.4 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.8.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.9 UniQure
11.9.1 UniQure Company Detail
11.9.2 UniQure Business Overview
11.9.3 UniQure Viral Vector and Plasmid DNA Introduction
11.9.4 UniQure Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.9.5 UniQure Recent Development
11.10 Aldevron
11.10.1 Aldevron Company Detail
11.10.2 Aldevron Business Overview
11.10.3 Aldevron Viral Vector and Plasmid DNA Introduction
11.10.4 Aldevron Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.10.5 Aldevron Recent Development
11.11 Richter-Helm
11.11.1 Richter-Helm Company Detail
11.11.2 Richter-Helm Business Overview
11.11.3 Richter-Helm Viral Vector and Plasmid DNA Introduction
11.11.4 Richter-Helm Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.11.5 Richter-Helm Recent Development
11.12 Eurogentec
11.12.1 Eurogentec Company Detail
11.12.2 Eurogentec Business Overview
11.12.3 Eurogentec Viral Vector and Plasmid DNA Introduction
11.12.4 Eurogentec Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.12.5 Eurogentec Recent Development
11.13 OBiO Technology
11.13.1 OBiO Technology Company Detail
11.13.2 OBiO Technology Business Overview
11.13.3 OBiO Technology Viral Vector and Plasmid DNA Introduction
11.13.4 OBiO Technology Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.13.5 OBiO Technology Recent Development
11.14 Yposkesi
11.14.1 Yposkesi Company Detail
11.14.2 Yposkesi Business Overview
11.14.3 Yposkesi Viral Vector and Plasmid DNA Introduction
11.14.4 Yposkesi Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.14.5 Yposkesi Recent Development
11.15 Cell and Gene Therapy Catapult
11.15.1 Cell and Gene Therapy Catapult Company Detail
11.15.2 Cell and Gene Therapy Catapult Business Overview
11.15.3 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Introduction
11.15.4 Cell and Gene Therapy Catapult Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.15.5 Cell and Gene Therapy Catapult Recent Development
11.16 MassBiologics
11.16.1 MassBiologics Company Detail
11.16.2 MassBiologics Business Overview
11.16.3 MassBiologics Viral Vector and Plasmid DNA Introduction
11.16.4 MassBiologics Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.16.5 MassBiologics Recent Development
11.17 Biovian
11.17.1 Biovian Company Detail
11.17.2 Biovian Business Overview
11.17.3 Biovian Viral Vector and Plasmid DNA Introduction
11.17.4 Biovian Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.17.5 Biovian Recent Development
11.18 VGXI
11.18.1 VGXI Company Detail
11.18.2 VGXI Business Overview
11.18.3 VGXI Viral Vector and Plasmid DNA Introduction
11.18.4 VGXI Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.18.5 VGXI Recent Development
11.19 Gene Synthesis
11.19.1 Gene Synthesis Company Detail
11.19.2 Gene Synthesis Business Overview
11.19.3 Gene Synthesis Viral Vector and Plasmid DNA Introduction
11.19.4 Gene Synthesis Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.19.5 Gene Synthesis Recent Development
11.20 PlasmidFactory
11.20.1 PlasmidFactory Company Detail
11.20.2 PlasmidFactory Business Overview
11.20.3 PlasmidFactory Viral Vector and Plasmid DNA Introduction
11.20.4 PlasmidFactory Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.20.5 PlasmidFactory Recent Development
11.21 Jikai Gene
11.21.1 Jikai Gene Company Detail
11.21.2 Jikai Gene Business Overview
11.21.3 Jikai Gene Viral Vector and Plasmid DNA Introduction
11.21.4 Jikai Gene Revenue in Viral Vector and Plasmid DNA Business (2017-2022)
11.21.5 Jikai Gene Recent Development
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Viral Vector and Plasmid DNA Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Viral Vector and Plasmid DNA Revenue Market Share by Type (2018-2023)
Table 7. Global Viral Vector and Plasmid DNA Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Viral Vector and Plasmid DNA Revenue Market Share by Type (2024-2029)
Table 9. Global Viral Vector and Plasmid DNA Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Viral Vector and Plasmid DNA Revenue Market Share by Application (2018-2023)
Table 11. Global Viral Vector and Plasmid DNA Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Viral Vector and Plasmid DNA Revenue Market Share by Application (2024-2029)
Table 13. Global Viral Vector and Plasmid DNA Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Viral Vector and Plasmid DNA Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Viral Vector and Plasmid DNA Market Share by Region (2018-2023)
Table 16. Global Viral Vector and Plasmid DNA Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Viral Vector and Plasmid DNA Market Share by Region (2024-2029)
Table 18. Viral Vector and Plasmid DNA Market Trends
Table 19. Viral Vector and Plasmid DNA Market Drivers
Table 20. Viral Vector and Plasmid DNA Market Challenges
Table 21. Viral Vector and Plasmid DNA Market Restraints
Table 22. Global Top Viral Vector and Plasmid DNA Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Viral Vector and Plasmid DNA Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Viral Vector and Plasmid DNA Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Viral Vector and Plasmid DNA, Headquarters and Area Served
Table 26. Global Viral Vector and Plasmid DNA Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Viral Vector and Plasmid DNA by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Viral Vector and Plasmid DNA Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Viral Vector and Plasmid DNA Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Viral Vector and Plasmid DNA Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Viral Vector and Plasmid DNA Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Viral Vector and Plasmid DNA Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Viral Vector and Plasmid DNA Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Viral Vector and Plasmid DNA Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Viral Vector and Plasmid DNA Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Viral Vector and Plasmid DNA Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Viral Vector and Plasmid DNA Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Viral Vector and Plasmid DNA Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Viral Vector and Plasmid DNA Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Viral Vector and Plasmid DNA Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country (2024-2029) & (US$ Million)
Table 45. Brammer Bio Company Detail
Table 46. Brammer Bio Business Overview
Table 47. Brammer Bio Viral Vector and Plasmid DNA Product
Table 48. Brammer Bio Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 49. Brammer Bio Recent Development
Table 50. Oxford BioMedica Company Detail
Table 51. Oxford BioMedica Business Overview
Table 52. Oxford BioMedica Viral Vector and Plasmid DNA Product
Table 53. Oxford BioMedica Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 54. Oxford BioMedica Recent Development
Table 55. Cobra Biologics Company Detail
Table 56. Cobra Biologics Business Overview
Table 57. Cobra Biologics Viral Vector and Plasmid DNA Product
Table 58. Cobra Biologics Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 59. Cobra Biologics Recent Development
Table 60. FinVector Company Detail
Table 61. FinVector Business Overview
Table 62. FinVector Viral Vector and Plasmid DNA Product
Table 63. FinVector Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 64. FinVector Recent Development
Table 65. Lonza Company Detail
Table 66. Lonza Business Overview
Table 67. Lonza Viral Vector and Plasmid DNA Product
Table 68. Lonza Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 69. Lonza Recent Development
Table 70. BioReliance Company Detail
Table 71. BioReliance Business Overview
Table 72. BioReliance Viral Vector and Plasmid DNA Product
Table 73. BioReliance Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 74. BioReliance Recent Development
Table 75. MolMed Company Detail
Table 76. MolMed Business Overview
Table 77. MolMed Viral Vector and Plasmid DNA Product
Table 78. MolMed Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 79. MolMed Recent Development
Table 80. FUJIFILM Diosynth Biotechnologies Company Detail
Table 81. FUJIFILM Diosynth Biotechnologies Business Overview
Table 82. FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Product
Table 83. FUJIFILM Diosynth Biotechnologies Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 84. FUJIFILM Diosynth Biotechnologies Recent Development
Table 85. UniQure Company Detail
Table 86. UniQure Business Overview
Table 87. UniQure Viral Vector and Plasmid DNA Product
Table 88. UniQure Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 89. UniQure Recent Development
Table 90. Aldevron Company Detail
Table 91. Aldevron Business Overview
Table 92. Aldevron Viral Vector and Plasmid DNA Product
Table 93. Aldevron Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 94. Aldevron Recent Development
Table 95. Richter-Helm Company Detail
Table 96. Richter-Helm Business Overview
Table 97. Richter-Helm Viral Vector and Plasmid DNAProduct
Table 98. Richter-Helm Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 99. Richter-Helm Recent Development
Table 100. Eurogentec Company Detail
Table 101. Eurogentec Business Overview
Table 102. Eurogentec Viral Vector and Plasmid DNAProduct
Table 103. Eurogentec Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 104. Eurogentec Recent Development
Table 105. OBiO Technology Company Detail
Table 106. OBiO Technology Business Overview
Table 107. OBiO Technology Viral Vector and Plasmid DNAProduct
Table 108. OBiO Technology Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 109. OBiO Technology Recent Development
Table 110. Yposkesi Company Detail
Table 111. Yposkesi Business Overview
Table 112. Yposkesi Viral Vector and Plasmid DNAProduct
Table 113. Yposkesi Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 114. Yposkesi Recent Development
Table 115. Cell and Gene Therapy Catapult Company Detail
Table 116. Cell and Gene Therapy Catapult Business Overview
Table 117. Cell and Gene Therapy Catapult Viral Vector and Plasmid DNAProduct
Table 118. Cell and Gene Therapy Catapult Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 119. Cell and Gene Therapy Catapult Recent Development
Table 120. MassBiologics Company Detail
Table 121. MassBiologics Business Overview
Table 122. MassBiologics Viral Vector and Plasmid DNAProduct
Table 123. MassBiologics Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 124. MassBiologics Recent Development
Table 125. Biovian Company Detail
Table 126. Biovian Business Overview
Table 127. Biovian Viral Vector and Plasmid DNAProduct
Table 128. Biovian Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 129. Biovian Recent Development
Table 130. VGXI Company Detail
Table 131. VGXI Business Overview
Table 132. VGXI Viral Vector and Plasmid DNAProduct
Table 133. VGXI Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 134. VGXI Recent Development
Table 135. Gene Synthesis Company Detail
Table 136. Gene Synthesis Business Overview
Table 137. Gene Synthesis Viral Vector and Plasmid DNAProduct
Table 138. Gene Synthesis Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 139. Gene Synthesis Recent Development
Table 140. PlasmidFactory Company Detail
Table 141. PlasmidFactory Business Overview
Table 142. PlasmidFactory Viral Vector and Plasmid DNAProduct
Table 143. PlasmidFactory Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 144. PlasmidFactory Recent Development
Table 145. Jikai Gene Company Detail
Table 146. Jikai Gene Business Overview
Table 147. Jikai Gene Viral Vector and Plasmid DNAProduct
Table 148. Jikai Gene Revenue in Viral Vector and Plasmid DNA Business (2017-2022) & (US$ Million)
Table 149. Jikai Gene Recent Development
Table 150. Brammer Bio Company Information
Table 151. Brammer Bio Business Overview
Table 152. Brammer Bio Viral Vector and Plasmid DNA Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 153. Brammer Bio Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 154. Brammer Bio Recent Development
Table 155. Oxford BioMedica Company Information
Table 156. Oxford BioMedica Business Overview
Table 157. Oxford BioMedica Viral Vector and Plasmid DNA Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 158. Oxford BioMedica Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 159. Oxford BioMedica Recent Development
Table 160. Cobra Biologics Company Information
Table 161. Cobra Biologics Business Overview
Table 162. Cobra Biologics Viral Vector and Plasmid DNA Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 163. Cobra Biologics Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 164. Cobra Biologics Recent Development
Table 165. FinVector Company Information
Table 166. FinVector Business Overview
Table 167. FinVector Viral Vector and Plasmid DNA Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 168. FinVector Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 169. FinVector Recent Development
Table 170. Lonza Company Information
Table 171. Lonza Business Overview
Table 172. Lonza Viral Vector and Plasmid DNA Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 173. Lonza Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 174. Lonza Recent Development
Table 175. BioReliance Company Information
Table 176. BioReliance Business Overview
Table 177. BioReliance Viral Vector and Plasmid DNA Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 178. BioReliance Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 179. BioReliance Recent Development
Table 180. MolMed Company Information
Table 181. MolMed Business Overview
Table 182. MolMed Viral Vector and Plasmid DNA Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 183. MolMed Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 184. MolMed Recent Development
Table 185. FUJIFILM Diosynth Biotechnologies Company Information
Table 186. FUJIFILM Diosynth Biotechnologies Business Overview
Table 187. FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 188. FUJIFILM Diosynth Biotechnologies Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 189. FUJIFILM Diosynth Biotechnologies Recent Development
Table 190. UniQure Company Information
Table 191. UniQure Business Overview
Table 192. UniQure Viral Vector and Plasmid DNA Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 193. UniQure Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 194. UniQure Recent Development
Table 195. Aldevron Company Information
Table 196. Aldevron Business Overview
Table 197. Aldevron Viral Vector and Plasmid DNA Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 198. Aldevron Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 199. Aldevron Recent Development
Table 200. Richter-Helm Company Information
Table 201. Richter-Helm Business Overview
Table 202. Richter-Helm Viral Vector and Plasmid DNARevenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 203. Richter-Helm Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 204. Richter-Helm Recent Development
Table 205. Eurogentec Company Information
Table 206. Eurogentec Business Overview
Table 207. Eurogentec Viral Vector and Plasmid DNARevenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 208. Eurogentec Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 209. Eurogentec Recent Development
Table 210. OBiO Technology Company Information
Table 211. OBiO Technology Business Overview
Table 212. OBiO Technology Viral Vector and Plasmid DNARevenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 213. OBiO Technology Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 214. OBiO Technology Recent Development
Table 215. Yposkesi Company Information
Table 216. Yposkesi Business Overview
Table 217. Yposkesi Viral Vector and Plasmid DNARevenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 218. Yposkesi Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 219. Yposkesi Recent Development
Table 220. Cell and Gene Therapy Catapult Company Information
Table 221. Cell and Gene Therapy Catapult Business Overview
Table 222. Cell and Gene Therapy Catapult Viral Vector and Plasmid DNARevenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 223. Cell and Gene Therapy Catapult Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 224. Cell and Gene Therapy Catapult Recent Development
Table 225. MassBiologics Company Information
Table 226. MassBiologics Business Overview
Table 227. MassBiologics Viral Vector and Plasmid DNARevenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 228. MassBiologics Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 229. MassBiologics Recent Development
Table 230. Biovian Company Information
Table 231. Biovian Business Overview
Table 232. Biovian Viral Vector and Plasmid DNARevenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 233. Biovian Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 234. Biovian Recent Development
Table 235. VGXI Company Information
Table 236. VGXI Business Overview
Table 237. VGXI Viral Vector and Plasmid DNARevenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 238. VGXI Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 239. VGXI Recent Development
Table 240. Gene Synthesis Company Information
Table 241. Gene Synthesis Business Overview
Table 242. Gene Synthesis Viral Vector and Plasmid DNARevenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 243. Gene Synthesis Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 244. Gene Synthesis Recent Development
Table 245. PlasmidFactory Company Information
Table 246. PlasmidFactory Business Overview
Table 247. PlasmidFactory Viral Vector and Plasmid DNARevenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 248. PlasmidFactory Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 249. PlasmidFactory Recent Development
Table 250. Jikai Gene Company Information
Table 251. Jikai Gene Business Overview
Table 252. Jikai Gene Viral Vector and Plasmid DNARevenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million)
Table 253. Jikai Gene Revenue in Viral Vector and Plasmid DNA Business (2018-2023) & (US$ Million) Portfolio
Table 254. Jikai Gene Recent Development
Table 255. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Viral Vector and Plasmid DNA Product Picture
Figure 5. Global Viral Vector and Plasmid DNA Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Viral Vector and Plasmid DNA Market Share by Type: 2022 VS 2029
Figure 7. Plasmid DNA Product Picture
Figure 8. Viral Vector Product Picture
Figure 9. Global Viral Vector and Plasmid DNA Market Size by Application (2023-2029) & (US$ Million)
Figure 10. Global Viral Vector and Plasmid DNA Market Share by Application: 2022 VS 2029

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings